What are the opening hours?

Monday 8am - 8pm Tuesday 8am - 8pm Wednesday 8am - 8pm Friday 8am - 8pm

Therapy Glow, Saint Petersburg, FL (2026)

06/02/2026

The U.S. Department of Veterans Affairs has initiated a landmark randomized, placebo-controlled trial evaluating M**A-assisted therapy for veterans with severe PTSD and alcohol use disorder. This federal endorsement signals institutional shifts toward psychedelic-assisted therapies, with rigorous protocols emphasizing integration therapy.

For clinicians working with veterans, this study highlights emerging access pathways and the need for careful adherence to treatment standards.

(Source: U.S. Department of Veterans Affairs, 2026)

Learn more at therapyglow.com

05/16/2026

Why does understanding yourself not always lead to change?

If you've ever sat in therapy thinking, "I know exactly why I do this—so why can't I stop?" you're not alone. This gap between insight and embodiment is now a recognized research focus, and it explains why so many psychologically-minded people feel stuck despite years of self-awareness work.

The research is clear: Cartesian mind-body dualism built into traditional talk therapy keeps us circling in our heads. Cognitive insight lives in explicit memory—what we can articulate and analyze. But trauma, attachment patterns, and survival strategies are stored in implicit memory: the body's autonomic responses, muscle tension, breath patterns, and nervous system states that operate below conscious awareness.

You can understand your childhood attachment wounds intellectually, map every defense mechanism, and still find your body reacting as if the threat is present. That's not a failure of insight—it's a nervous system that hasn't received the memo. Dissociation, the brain's brilliant protection system, creates a firewall between what you know and what you feel. Your mind might be ready to heal, but your body is still in survival mode.

Here's what bridges the gap: interoceptive awareness (noticing internal bodily sensations), somatic processing (working directly with the body's stored responses), co-regulation (using therapeutic relationship to stabilize your nervous system), and experiential learning (engaging the body in real-time, not just reflecting on it afterward). Research now validates what many of us have felt: insight alone cannot reach the implicit knowledge your body carries. You need approaches that meet your nervous system where it is.

Somatic Experiencing, Sensorimotor Psychotherapy, movement-based therapies, breathwork, and nervous system regulation aren't "alternative"—they're essential for people whose insight has outpaced their capacity for embodied change. This is not about thinking your way into a new way of being. It's about allowing your body to update its threat detection system so you can finally live the life your insight has been pointing toward.

If you're tired of understanding everything and changing nothing, this is the work. Your body isn't resisting change—it's waiting for an invitation in its own language. (Source: Frontiers in Psychology, Multiple university studies, 2026)

Learn more at therapyglow.com

05/15/2026

The regulatory landscape for psychedelic-assisted therapy just shifted dramatically.

Following President Trump's April 18, 2026 executive order, the FDA issued Commissioner's National Priority Vouchers (CNPVs) for M**A (PTSD), psilocybin (treatment-resistant depression and major depressive disorder), and methylone (PTSD research). This fast-track designation shortens approval timelines from months to potentially 1-2 months in certain cases—an unprecedented acceleration for treatments that have spent decades in regulatory limbo.

This isn't just about faster access. It's about recognition that for certain populations—particularly those with treatment-resistant PTSD and depression—existing evidence-based interventions aren't enough. M**A-assisted therapy for PTSD and psilocybin for depression are on accelerated approval pathways, with COMPASS Pathways' COMP360 (synthetic psilocybin) aiming for rolling NDA submission in Q4 2026 and potential approval by late 2026 or early 2027.

Multiple VA-funded trials are underway for PTSD, alcohol use disorder, treatment-resistant depression, and anxiety disorders among veterans. The clinical model isn't standalone pharmacotherapy—it's structured psychotherapy sessions combined with pharmacological intervention. Preparation, dosing sessions with trained therapists, and integration work are all essential components.

For those of us working with clients whose insight has outpaced their capacity for change—who understand their patterns deeply but remain stuck in cycles of trauma response—this represents a potential expansion of our treatment toolkit. Psychedelic-assisted therapy appears to create a neuroplastic window where deeply entrenched patterns become temporarily more malleable, allowing therapeutic work that might otherwise take years to occur in a compressed timeframe.

The research is compelling. The therapy protocols are rigorous. And the regulatory pathway is now moving faster than anyone anticipated. For clinicians, this means preparing for integration into practice—understanding the protocols, recognizing appropriate candidates, and staying current on approval timelines and training requirements.

This is emerging science meeting urgent clinical need. Worth paying attention to.

(Source: FDA/Pharmacy Times, AHA, April 18-24, 2026)

Learn more at therapyglow.com

**A

05/15/2026

Transcranial Ultrasound Stimulation is emerging as a precision non-invasive brain stimulation tool capable of reaching deeper brain structures that regulate emotion and self-regulation—structures like the thalamus and amygdala that have been out of reach for standard non-invasive brain stimulation methods.

This matters because most existing NIBS techniques (like TMS) can only target cortical areas. TUS addresses a fundamental limitation: it can modulate deep emotional regulation networks that are central to trauma, mood disorders, and emotional dysregulation.

The research positions TUS as a "neuroplasticity primer"—a way to induce transient neuroplastic states that may enhance the effectiveness of psychotherapy. This complements what we already know: psychotherapy produces measurable neuroplastic changes, but those changes typically emerge after several months of consistent therapeutic engagement.

What's clinically interesting here is the potential for integration. TUS isn't a replacement for therapy—it's a tool that may accelerate or deepen the neurobiological shifts that therapy already facilitates. For treatment-resistant cases, particularly clients with profound emotional regulation impairments, this could represent a meaningful adjunct.

We're not there yet—this is still early-stage research. But the trajectory is worth tracking. As brain stimulation technologies evolve, the question isn't whether they replace psychotherapy, but how they integrate with it. The brain changes through relationship and meaning-making. Technology may eventually help us reach the neural substrates that support that work more efficiently.

For now: monitor emerging TUS research and clinical availability. If you work with clients whose emotional regulation systems feel profoundly stuck despite sustained therapeutic effort, this is a development to keep on your radar.

(Source: Frontiers in Human Neuroscience, 2026)

Learn more at therapyglow.com

05/15/2026

The most comprehensive evaluation of ADHD treatments ever conducted is now available—an umbrella review synthesizing over 200 meta-analyses to clarify what actually works.

The findings confirm medication remains the most reliable intervention for both children and adults, with cognitive behavioral therapy also showing strong evidence for adults in short-term clinical trials. But here's the limitation: all evidence is restricted to short-term outcomes, despite most people receiving long-term treatment.

Alternative interventions—acupuncture, mindfulness, exercise—showed potential, but the evidence quality remains low due to small samples and high risk of bias. Mindfulness was the only intervention demonstrating large benefits at extended follow-up, though the research base is still limited.

What makes this work truly valuable is the creation of the Evidence-Based Interventions for ADHD database (ebiadhd-database.org)—the first continuously updated, rigorously synthesized platform designed for shared decision-making between clinicians and clients. Rather than relying on outdated guidelines or marketing claims, you now have access to real-time evidence quality ratings.

For clinicians working with high-insight adults whose executive function challenges have contributed to the gap between insight and embodied change, this resource offers a foundation for informed treatment planning. ADHD often hides beneath presenting concerns like chronic procrastination, relationship conflict, or the experience of "knowing what to do but not being able to do it."

The evidence tells us medication and CBT lead, but it also reveals how much we still don't know about long-term efficacy and the real-world integration of interventions. Shared decision-making tools like this database make room for that complexity rather than reducing treatment to a single prescription.

(Source: The BMJ, Université Paris Nanterre, Institut Robert-Debré du Cerveau de l'Enfant, University of Southampton, 2026)

Learn more at therapyglow.com

05/14/2026

Sometimes the most powerful interventions are the simplest.

A recent study from Oxford University found that playing Tetris—yes, the block-stacking game—dramatically reduced intrusive trauma memories within one month. Some participants became symptom-free after six months. The intervention also significantly reduced general PTSD symptoms.

The mechanism is elegantly straightforward: Tetris's visuospatial demands compete for the same working memory resources that trauma intrusions require. By engaging visual-spatial processing during the reconsolidation window, the game interrupts the brain's tendency to replay the trauma loop. This isn't distraction—it's strategic interference with memory consolidation.

What makes this compelling isn't just efficacy. It's accessibility. No specialized equipment. No prolonged exposure protocols. No need to recount the trauma in clinical settings. For clients who face barriers to traditional trauma therapy—whether financial, logistical, or emotional—this represents a genuinely low-threshold intervention.

Of course, this doesn't replace comprehensive trauma treatment. But it challenges our assumptions about complexity. Sometimes neuroplasticity doesn't require elaborate protocols. Sometimes it requires the right task at the right time, leveraging what we know about how memory works.

For clinicians: this could inform brief interventions for acute trauma, intrusive memories, or as an adjunct during the early stages of trauma processing. The takeaway isn't 'prescribe Tetris'—it's that understanding the neuroscience of memory reconsolidation opens doors to interventions we might not have considered.

The brain is more malleable than we think. And sometimes, the tools we need are already in our hands.

(Source: Oxford University, February 2026)

Learn more at therapyglow.com

05/14/2026

The college mental health crisis has forced innovation—and the data is striking. Smartphone-based digital therapy with coaching proved more effective than traditional campus mental health clinic referrals for students with anxiety, depression, and eating disorders. Not just more accessible. More effective.

This isn't about replacing human connection. It's about meeting young adults where they already are—on their phones, navigating a world that moves faster than appointment availability. The interventions reduced symptoms while dramatically increasing access to care, addressing the gap between need and service availability in a population that has been systematically underserved by traditional models.

For those of us who work with young adults, this is worth considering. Many clients in their twenties and thirties prefer app-based support—not as a replacement for depth work, but as a scaffold. A way to practice skills between sessions. A bridge when therapy feels too far away or too formal.

The hybrid model is where this gets interesting: digital tools for skill-building and daily support, combined with periodic clinical check-ins for relational depth and meaning-making. This isn't either/or. It's both/and—matching the intervention to the person's readiness, preference, and context.

The question isn't whether technology belongs in mental health care. It's already here. The question is: how do we integrate it thoughtfully, without losing what makes therapy transformative—the relationship, the attunement, the space to be seen?

(Source: UCLA & Washington University, 2026)

Learn more at therapyglow.com

05/14/2026

MRI-Guided TMS Reduces PTSD Symptoms by Calming the Fear Center

A landmark advance in precision neurostimulation: MRI-guided transcranial magnetic stimulation (TMS) targeting the amygdala has produced significant, lasting reductions in PTSD symptoms—without requiring trauma recounting.

In a randomized controlled trial with 47 participants, 74% in the active TMS group experienced clinically meaningful symptom reduction after just two weeks of treatment. Effects persisted for at least six months. The intervention reduced right amygdala reactivity to threat, addressing the neurobiological substrate of hypervigilance and re-experiencing symptoms.

This represents the first MRI-individualized TMS approach for PTSD, marking a paradigm shift toward biology-based, personalized interventions.

Why this matters clinically:

Unlike traditional talk therapy, TMS doesn't require clients to recount or relive traumatic experiences—potentially reducing treatment barriers for those who find exposure-based approaches intolerable or insufficient. Participants described qualitative changes in how they emotionally experienced trauma, including improved nightmare management and reduced reactivity to trauma reminders.

This approach doesn't replace psychotherapy—it creates neurobiological conditions that may make psychotherapy more effective. By directly modulating amygdala hyperreactivity, TMS may open a window for clients whose nervous systems remain locked in threat mode despite insight and skills.

For clinicians working with treatment-resistant PTSD or clients for whom trauma-focused therapy feels too destabilizing, MRI-guided TMS offers a complementary path. It's especially relevant for those whose insight has outpaced their capacity for change—who understand their trauma intellectually but remain physiologically imprisoned by it.

The precision matters: this isn't broad-spectrum neuromodulation. MRI guidance allows clinicians to target the exact neural structures driving an individual's symptoms, honoring the reality that trauma lives in the body and brain, not just the narrative.

As this technology becomes more accessible, it raises important questions about how we sequence and combine interventions. When should we consider neurostimulation? How do we integrate it with relational and somatic therapies? What does it mean for our understanding of trauma treatment when we can directly modulate the fear center?

(Source: Emory University School of Medicine, The American Journal of Psychiatry, April 2026)

Learn more at therapyglow.com

05/13/2026

Your brain has specific architecture for emotion regulation — and it's trainable.

Dartmouth neuroscientists have precisely mapped the brain regions uniquely responsible for emotion regulation (reappraisal), distinct from all other cognitive processes. These areas in the anterior prefrontal cortex and higher-level cortical hierarchies don't just light up during emotional control — they represent specialized neural real estate dedicated to this function alone.

This matters clinically because it validates what many clients experience: that knowing what to do doesn't automatically translate into being able to do it. Insight lives in one part of the brain. The capacity to regulate emotion in real time lives in another. And that capacity is built through repetitive practice, not intellectual understanding.

When we ask clients to practice reappraisal skills — reframing catastrophic thoughts, shifting perspective on distressing situations, consciously choosing interpretations that reduce emotional intensity — we're not asking them to "think positive." We're asking them to strengthen specific neural pathways. Each time they practice, they're building the brain architecture that makes regulation feel less effortful over time.

For clients whose insight has outpaced their capacity for change, this neuroscience provides a tangible explanation: you understand the problem deeply, but the circuits responsible for implementing that understanding in emotionally charged moments are still under construction. The work isn't about gaining more insight. It's about consistent, embodied practice that consolidates those pathways.

Frame skills practice as neurobiological change, not coping strategies. Clients who understand they're literally building brain structure often approach practice with more patience and persistence. It shifts the question from "Why can't I just do this?" to "How do I strengthen this over time?"

The brain is remarkably plastic, but plasticity requires repetition. Emotion regulation is a learnable skill with measurable neurobiological correlates. When clients practice reappraisal consistently — even when it feels awkward or insufficient — they are creating structural change in the exact brain regions responsible for that capacity.

This is the bridge between insight and embodiment.

(Source: Dartmouth University, 2024 neuroscience study)

Learn more at therapyglow.com

05/13/2026

Psilocybin-Assisted Therapy Shows Promise for Co***ne Use Disorder

A University of Alabama at Birmingham clinical trial published in JAMA Network Open found psilocybin-assisted therapy to be both safe and effective for co***ne use disorder—a critical finding given the historical lack of FDA-approved pharmacological treatments for stimulant addiction.

Participants receiving psilocybin showed higher percentages of co***ne-abstinent days and greater likelihood of complete abstinence compared to placebo controls. This isn't about the compound alone doing the work. Psilocybin appears to open a neuroplastic window—a period of heightened flexibility in the brain's reward circuitry, fear conditioning, and narrative structures about self and substance use. Within that window, therapy can reach deeper.

For clients who have cycled through traditional abstinence-based programs without sustained change, psychedelic-assisted therapy may offer something qualitatively different: a chance to disentangle identity from addiction, to reprocess the emotional drivers underneath compulsive use, and to access motivation that's been buried under shame.

The regulatory landscape is shifting rapidly. As these protocols move closer to accessibility, clinicians will need to understand not just the pharmacology but the therapeutic architecture—preparation, the session itself, and integration work afterward. The medicine creates the opening. The therapy does the healing.

If you work with clients struggling with treatment-resistant substance use, stay informed. The field is moving quickly, and referral pathways will soon be more available than most of us anticipated.

(Source: University of Alabama at Birmingham, JAMA Network Open, 2026)

Learn more at therapyglow.com

***neAddiction

Therapy Glow

06/02/2026

05/16/2026

05/15/2026

05/15/2026

05/15/2026

05/14/2026

05/14/2026

05/14/2026

05/13/2026

05/13/2026

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Monday	8am - 8pm
Tuesday	8am - 8pm
Wednesday	8am - 8pm
Friday	8am - 8pm